Sphingolipid Synthesis Inhibition by Myriocin Administration Enhances Lipid Consumption and Ameliorates Lipid Response to Myocardial Ischemia Reperfusion Injury
Open Access
- 9 August 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 10, 986
Abstract
Myocardial infarct requires prompt thrombolytic therapy or primary percutaneous coronary intervention to limit the extent of necrosis, but reperfusion creates additional damage. Along with reperfusion, a maladaptive remodeling phase might occur and it is often associated with inflammation, oxidative stress, as well as a reduced ability to recover metabolism homeostasis. Infarcted individuals can exhibit reduced lipid turnover and their accumulation in cardiomyocytes, which is linked to a deregulation of peroxisome proliferator activated receptors (PPARs), controlling fatty acids metabolism, energy production, and the anti-inflammatory response. We previously demonstrated that Myriocin can be effectively used as post-conditioning therapeutic to limit ischemia/reperfusion-induced inflammation, oxidative stress, and infarct size, in a murine model. In this follow-up study, we demonstrate that Myriocin has a critical regulatory role in cardiac remodeling and energy production, by up-regulating the transcriptional factor EB, PPARs nuclear receptors and genes involved in fatty acids metabolism, such as VLDL receptor, Fatp1, CD36, Fabp3, Cpts, and mitochondrial FA dehydrogenases. The overall effects are represented by an increased β–oxidation, together with an improved electron transport chain and energy production. The potent immunomodulatory and metabolism regulatory effects of Myriocin elicit the molecule as a promising pharmacological tool for post-conditioning therapy of myocardial ischemia/reperfusion injury.Keywords
This publication has 78 references indexed in Scilit:
- Lipid Metabolism and Toxicity in the HeartCell Metabolism, 2012
- Myocardial Ischemia Reperfusion InjurySeminars in Cardiothoracic and Vascular Anesthesia, 2012
- Peroxisome proliferator-activated receptor-γ regulates the expression and function of very-low-density lipoprotein receptorAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP‐1 cells, without decreasing the beneficial effects on cholesterol synthesisBritish Journal of Pharmacology, 2009
- Myocardial lipid accumulation and lipotoxicity in heart failureJournal of Lipid Research, 2009
- Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonistsCardiovascular Research, 2008
- Reverse changes in cardiac substrate oxidation in dogs recovering from heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Inflammatory Pathways Are Activated during Cardiomyocyte Hypertrophy and Attenuated by Peroxisome Proliferator-activated Receptors PPARα and PPARδJournal of Biological Chemistry, 2008
- Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysisBritish Journal of Pharmacology, 2008
- PPARs in the Control of Uncoupling Proteins Gene ExpressionPPAR Research, 2006